Improvement of daratumumab- or elotuzumab-mediated NK cell activity by the bi-specific 4-1BB agonist, DARPin α-FAPx4–1BB: A preclinical study in multiple myeloma
Article in Biomedicine & Pharmacotherapy (June 2024)
The most recent citing publications are shown below. View all 59 publications that cite this research output on Dimensions.
Article in Biomedicine & Pharmacotherapy (June 2024)
Article in International Journal of Molecular Sciences (December 2023)
Article in Molecular Cancer Research (October 2023)